Skip to main content
. 2011 May 11;31(19):7190–7198. doi: 10.1523/JNEUROSCI.1171-11.2011

Figure 6.

Figure 6.

A, Duration of ON-time with psychosis-like behavior in marmosets treated with l-DOPA and R-MDMA (1, 3, or 10 mg/kg) or vehicle. R-MDMA had no effect on the duration of ON-time with psychosis-like behavior (p > 0.05). B, Duration of ON-time with disabling psychosis-like behavior in marmosets treated with l-DOPA and R-MDMA (1, 3, or 10 mg/kg) or vehicle. R-MDMA (3 and 10 mg/kg) significantly decreased the duration of ON-time with disabling psychosis-like behavior when compared to l-DOPA vehicle (p < 0.01 for 3 mg/kg R-MDMA; p < 0.05 for 10 mg/kg R-MDMA). C, Duration of ON-time with nondisabling psychosis-like behavior in marmosets treated with l-DOPA and R-MDMA (1, 3, or 10 mg/kg) or vehicle. R-MDMA (3 mg/kg) significantly increased the duration of ON-time with nondisabling psychosis-like behavior when compared to l-DOPA vehicle (p < 0.01). D, Duration of ON-time without psychosis-like behavior in marmosets treated with l-DOPA and R-MDMA (1, 3, or 10 mg/kg) or vehicle. R-MDMA (3 mg/kg) significantly increased the duration of ON-time without psychosis-like behavior when compared to l-DOPA vehicle (p < 0.05). E, Duration of ON-time without disabling psychosis-like behavior in marmosets treated with l-DOPA and R-MDMA (1, 3, or 10 mg/kg) or vehicle. R-MDMA (3 and 10 mg/kg) significantly increased the duration of ON-time without disabling psychosis-like behavior when compared to l-DOPA vehicle (p < 0.001 for 3 mg/kg R-MDMA; p < 0.05 for 10 mg/kg R-MDMA). F, Peak-dose psychosis-like behavior (60–150 min after l-DOPA administration) in marmosets treated with l-DOPA and R-MDMA (1, 3, or 10 mg/kg) or vehicle. R-MDMA did not significantly alter the severity of peak-dose dyskinesia (p > 0.05). G, Duration of ON-time with psychosis-like behavior in marmosets treated with l-DOPA and S-MDMA (1, 3, or 10 mg/kg) or vehicle. S-MDMA had no effect on the duration of ON-time with psychosis-like behavior (p > 0.05). H, Duration of ON-time with disabling psychosis-like behavior in marmosets treated with l-DOPA and S-MDMA (1, 3, or 10 mg/kg) or vehicle. S-MDMA had no effect on the duration of ON-time with disabling psychosis-like behavior (p > 0.05). I, Duration of ON-time with nondisabling psychosis-like behavior in marmosets treated with l-DOPA and S-MDMA (1, 3, or 10 mg/kg) or vehicle. S-MDMA had no effect on the duration of ON-time with nondisabling psychosis-like behavior (p > 0.05). J, Duration of ON-time without psychosis-like behavior in marmosets treated with l-DOPA and S-MDMA (1, 3, or 10 mg/kg) or vehicle. Duration of ON-time without psychosis-like behavior was significantly longer in the 1 mg/kg S-MDMA treatment when compared to the 10 mg/kg S-MDMA treatment (p < 0.05). K, Duration of ON-time without disabling psychosis-like behavior in marmosets treated with l-DOPA and S-MDMA (1, 3, or 10 mg/kg) or vehicle. S-MDMA had no effect on the duration of ON-time without disabling psychosis-like behavior (p > 0.05). L, Peak-dose psychosis-like behavior (60–150 min after l-DOPA administration) in marmosets treated with l-DOPA and S-MDMA (1, 3, or 10 mg/kg) or vehicle. S-MDMA did not significantly alter the severity of peak-dose dyskinesia (p > 0.05). Data are presented as the mean ± SEM ON-time duration (A–E, G–K). F, L, Bars represent the median score for psychosis-like behavior, and the dots represent the individual score of each animal; the maximal possible score (most severe disability) was 36. For graphs F and L, on the y-axis, 9 is mild, 18 is moderate, 27 is marked, and 36 is severe. *p < 0.05; **p < 0.01; ***p < 0.001.